Blue Dye 2 vs Yellow Dye 6: which is worse?

What is Blue Dye 2?

Blue Dye 2 (Indigotine/Indigo Carmine) is a synthetic disulfonated derivative of indigo. Unlike natural indigo from the indigo plant, the FD&C version is synthetically manufactured from petroleum. It produces a dark royal blue to indigo color and is used in food, pharmaceuticals, and medical diagnostics.

What is Yellow Dye 6?

Yellow Dye 6 (Sunset Yellow FCF) is a synthetic orange-yellow azo dye derived from petroleum. It produces a bright orange-yellow color and is structurally similar to Yellow 5 but produces a more orange shade. Its chemical formula is C16H10N2Na2O7S2.

Documented risks

Blue Dye 2: Animal studies conducted in the 1980s found that high-dose Blue Dye 2 caused brain tumors in male rats. An NTP bioassay (1987) found statistically significant increases in brain gliomas (astrocytomas) in male rats given high doses. The FDA reviewed these findings and determined that the doses far exceeded typical human dietary exposure. Nonetheless, the tumor finding remains in the scientific record as a concerning data point. EFSA's 2010 safety evaluation of Indigo Carmine (E132) reached an unusual conclusion: it could not establish an ADI due to data limitations, including the brain tumor findings. This means EFSA adopted an implicit conservative position — it neither declared Blue 2 safe nor formally banned it, but the absence of an established ADI signals scientific uncertainty. In medical diagnostic use, high intravenous doses of Indigo Carmine can cause hypertension, bradycardia, and in rare cases anaphylaxis. These are dose-specific clinical pharmacological effects, not relevant to dietary consumption at food use levels. Blue 2 was not included in the 2007 Lancet hyperactivity study. Limited direct research links Blue 2 to behavioral effects. The FDA's April 2025 announcement includes Blue 2 in the class of petroleum-based synthetic dyes to be phased out of the US food supply, reflecting updated policy on the category rather than specific new Blue 2 toxicity data.

Yellow Dye 6: Yellow Dye 6 was included in the 2007 Lancet study (McCann et al.), which found that a mixture of six dyes including Yellow 6 and sodium benzoate significantly increased hyperactivity in children. EFSA confirmed the effect warranted mandatory warning labels in the EU. EFSA's 2009 re-evaluation examined animal carcinogenicity data and found some studies showing adrenal tumors in male mice at high doses. EFSA set an ADI of 2.5 mg/kg body weight — lower than Yellow 5's ADI of 7.5 mg/kg, reflecting greater concern. The review noted limitations in the available data. Impurity concerns: commercial batches of Yellow 6 have been found to contain aromatic amine impurities including benzidine and 4-aminobiphenyl — both IARC Group 1 human carcinogens. A 1992 CSPI analysis documented these impurities, citing them as reason for concern. A 2007 study in Toxicological Sciences found Yellow 6 altered zinc and iron biomarker levels in rat blood at high doses, raising mineral metabolism concerns. Human relevance at typical exposure is unclear. Hypersensitivity reactions including urticaria, rhinitis, and contact dermatitis are documented. Cross-reactivity with aspirin is reported similarly to Yellow 5. In April 2025, the FDA announced plans to phase out Yellow 6 with other petroleum-based dyes.